In vitro studies proved that EGCG counteracted breast cancer progression, attenuating the expression of miR-25 [127], while genistein reduced the expression levels of onco-miR-155, the regulator of several tumor suppressors as PTEN and p27, and impaired cell mobility via p21 activated kinase 2 (PAK2) and miR-23b upregulation in breast cancer cells [128,129]. This evidence concerns the gene CDKN1B and breast cancer.